These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36977736)

  • 21. The Pan-Cancer Landscape of Crosstalk Between TRP Family and Tumour Microenvironment Relevant to Prognosis and Immunotherapy Response.
    Wu G; He M; Yin X; Wang W; Zhou J; Ren K; Chen X; Xue Q
    Front Immunol; 2022; 13():837665. PubMed ID: 35493463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
    Song J; Yang R; Wei R; Du Y; He P; Liu X
    Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
    Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
    Front Immunol; 2022; 13():844736. PubMed ID: 35592314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker.
    Qiu Y; Wang H; Liao P; Xu B; Hu R; Yang Y; Li Y
    BMC Genom Data; 2022 Jan; 23(1):7. PubMed ID: 35033016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature.
    Mohan CD; Rangappa S; Preetham HD; Chandra Nayaka S; Gupta VK; Basappa S; Sethi G; Rangappa KS
    Semin Cancer Biol; 2022 May; 80():157-182. PubMed ID: 32325172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 28. A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence.
    Wu Z; Uhl B; Gires O; Reichel CA
    J Biomed Sci; 2023 Mar; 30(1):21. PubMed ID: 36978029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and immunological role of FCER1G in pan-cancer.
    Zhang X; Cai J; Song F; Yang Z
    Pathol Res Pract; 2022 Dec; 240():154174. PubMed ID: 36332324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ZIC2 is downregulated and represses tumor growth via the regulation of STAT3 in breast cancer.
    Liu ZH; Chen ML; Zhang Q; Zhang Y; An X; Luo YL; Liu XM; Liu SX; Liu Q; Yang T; Liu YM; Liu BL; Zhou AJ; Li MZ; Liu YJ; Liu ZX; Zhong Q
    Int J Cancer; 2020 Jul; 147(2):505-518. PubMed ID: 32064600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-Cancer Analysis of the TRP Family, Especially TRPV4 and TRPC4, and Its Expression Correlated with Prognosis, Tumor Microenvironment, and Treatment Sensitivity.
    Chen Z; Zhao Y; Tian Y; Cao R; Shang D
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer Analysis.
    Zhao Q; Zhang Z; Wu Y
    Ann Clin Lab Sci; 2022 Mar; 52(2):185-195. PubMed ID: 35414497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell death-related biomarker SLC2A1 has a significant role in prognosis prediction and immunotherapy efficacy evaluation in pan-cancer.
    Wang Y; Wang K; Zhang H; Jia X; Li X; Sun S; Sun D
    Front Genet; 2022; 13():1068462. PubMed ID: 36712872
    [No Abstract]   [Full Text] [Related]  

  • 34. The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma.
    Wu HT; Liu J; Li GW; Shen JX; Huang YT
    Oncotarget; 2017 May; 8(22):36279-36288. PubMed ID: 28422733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NCAPG2 could be an immunological and prognostic biomarker: From pan-cancer analysis to pancreatic cancer validation.
    Wang Q; Li Z; Zhou S; Li Z; Huang X; He Y; Zhang Y; Zhao X; Tang Y; Xu M
    Front Immunol; 2023; 14():1097403. PubMed ID: 36776838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis.
    Zhao G; Song D; Wu J; Yang S; Shi S; Cui X; Ren H; Zhang B
    Front Immunol; 2022; 13():955091. PubMed ID: 36052059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential value of PRKDC as a therapeutic target and prognostic biomarker in pan-cancer.
    Yang X; Yang F; Lan L; Wen N; Li H; Sun X
    Medicine (Baltimore); 2022 Jul; 101(27):e29628. PubMed ID: 35801800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-Cancer Analysis of B4GALNT1 as a Potential Prognostic and Immunological Biomarker.
    Yi H; Lin Y; Li Y; Guo Y; Yuan L; Mao Y
    J Immunol Res; 2022; 2022():4355890. PubMed ID: 35935585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
    Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
    Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.